Is Viemed Healthcare, Inc. (VMD) Overvalued?
We dive into why Viemed Healthcare, Inc. (VMD) could be considered overvalued on 2026-08-17, based on AAII’s Value Score and Grade.Jenna Brashear
Stock Evaluator: Viemed Healthcare, Inc. (VMD)
Viemed Healthcare, Inc. VMD
$8.85
0.28
3.27%
August 21, 2026 4:00:00 PM
EST
Volume: 1,072,865
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Providers & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. It also sells and rents HME devices, such as non-invasive and invasive ventilators, positive airway pressure (PAP) machines, durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment. In addition, the company provides neuromuscular care and oxygen therapy services; and sleep apnea management which provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, it offers in-home sleep apnea testing services; and breast pumps and related lactation equipment and supplies, including fulfillment and support services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.
Commentary & Analysis
Why Viemed Healthcare, Inc.’s (VMD) Stock Is Down 17.62%
As of Tuesday, August 04, Viemed Healthcare, Inc.’s VMD share price has dipped by 17.62%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Viemed Healthcare, Inc.’s (VMD) Stock Is Down 14.71%
As of Tuesday, August 04, Viemed Healthcare, Inc.’s VMD share price has dipped by 14.71%, which has investors questioning if this is right time to buy.Michael Rose
Why Viemed Healthcare, Inc.’s (VMD) Stock Is Up 5.11%
As of Thursday, May 07, Viemed Healthcare, Inc.’s VMD share price has surged by 5.11%, which has investors questioning if this is right time to sell.Michael Rose
Why Viemed Healthcare, Inc.’s (VMD) Stock Is Down 10.41%
As of Wednesday, May 06, Viemed Healthcare, Inc.’s VMD share price has dipped by 10.41%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | VMD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $337.1 | $1,968.0 | 32% |
|
| Shares Out (Mil) | 41.1 | 77.7 | 43% |
|
| Institutional Ownership | 82.0% | 86.6% | 50% |
|
| Float (Mil) | 30.7 | 52.1 | 37% |
|
| Beta | 1.12 | 0.75 | 67% |
|
| Avg Daily Volume (000s) | 533 | 612 | 59% |
|
| Price Change (52-week) |
29.0% | 79.8% | 67% |
|
| Growth | VMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 15.5% | 10.9% | 74% |
|
| Net Income (5yr) | (13.9%) | (1.6%) | 26% |
|
| EPS (5yr) | (13.9%) | 0.3% | 19 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.3%) | (17.9%) | 41% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | VMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $302 | $1,504 | 36% |
|
| Net Income (TTM) (Mil) | $15 | $28 | 47% |
|
| EPS (TTM) | $0.378 | $0.200 | 51% |
|
| Operating Cash Flow (TTM) (Mil) | $61 | $162 | 48% |
|
| Net Cash Flow (TTM) (Mil) | ($9) | $9 | 31% |
|
| Long-Term Debt (Q1) (Mil) | $10 | $338 | 28% |
|
| Enterprise Value (Q1) (Mil) | $378 | $2,416 | 32% |
|
| Valuation | VMD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.34 | 2.82 | 55% |
|
| P/E | 24.5 | 26.0 | 61% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | VMD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 57.5% | 27.8% | 70% |
|
| Net Margin | 4.8% | 1.2% | 47% |
|
| ROA | 7.5% | 2.2% | 81% |
|
| ROE | 10.2% | 7.2% | 58% |
|
| Liabilities to Assets | 28.5% | 58.6% | 20% |
|
| F-Score | 5 | 5 | 50% |
|
Passing Stock Screens
As of 8/21/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Price-to-Sales Screen
Factors: Value, Growth
Research indicates that using price-to-sales ratios may lead to better investment results than price-to-book-value ratios or price-earnings ratios.
| Performance Since Inception: | 13.0% |
| +/- S&P 500: | +5.5 |
